Replimune Group Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Replimune Group hat ein Gesamteigenkapital von $381.5M und eine Gesamtverschuldung von $45.6M, was einen Verschuldungsgrad von 11.9% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $498.2M bzw. $116.7M.

Wichtige Informationen

11.9%

Verhältnis von Schulden zu Eigenkapital

US$45.57m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$432.06m
Eigenkapital	US$381.46m
Gesamtverbindlichkeiten	US$116.74m
Gesamtvermögen	US$498.20m

Jüngste Berichte zur Finanzlage

Recent updates

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Nov 23

Replimune: Strong Data In A Highly Differentiated Space

Sep 03

Is Replimune Group (NASDAQ:REPL) Using Debt Sensibly?

Aug 16

Replimune: Continuing To Justify The Bear Thesis (For Now)

May 22

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Feb 06

Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer

Jan 23

Calculating The Intrinsic Value Of Replimune Group, Inc. (NASDAQ:REPL)

Dec 25

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Jul 13

Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?

Apr 05

A Look At The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Jan 06

Replimune secures $200M term loan

Oct 07

Replimune: Recent Developments Strengthen Bull Thesis

Aug 12

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Aug 06

Replimune Group GAAP EPS of -$0.78 misses by $0.15

Aug 04

Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate

Jun 24

We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate

Apr 04

Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth

Dec 16

Replimune: In The 'Buy Zone' Again

Oct 01

Estimating The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Sep 02

Replimune Group (NASDAQ:REPL) Is In A Strong Position To Grow Its Business

May 24

Replimune: Oncolytic Immunotherapy Pioneer Gaining Momentum In The Clinic

Apr 30

We're Interested To See How Replimune Group (NASDAQ:REPL) Uses Its Cash Hoard To Grow

Feb 08

Replimune Group EPS misses by $0.03

Feb 04

Dosing underway in Replimune's early-stage cancer study with gene therapy

Jan 05

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: REPLDie kurzfristigen Aktiva des Unternehmens ($442.6M) übersteigen seine kurzfristigen Passiva ($43.8M).

Langfristige Verbindlichkeiten: REPLDie kurzfristigen Vermögenswerte des Unternehmens ($442.6M) übersteigen seine langfristigen Verbindlichkeiten ($73.0M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: REPL über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: REPLDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 8% auf 11.9% gestiegen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: REPL auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.

Vorhersage Cash Runway: REPL verfügt über eine ausreichende Liquiditätsreserve für 2.1 Jahre, wenn der freie Cashflow weiterhin mit historischen Raten von 30% pro Jahr abnimmt.

Replimune Group Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Is Replimune Group (NASDAQ:REPL) Using Debt Sensibly?

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Recent updates

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

New minor risk - Share price stability

Replimune Group, Inc. Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

Replimune Presents Late-Breaking Abstract Featuring Data from Ignyte Clinical Trial of Rp1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At the 39Th Annual Meeting of the Society for Immunotherapy of Cancer (Sitc 2024)

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At European Society for Medical Oncology Congress 2024

Replimune: Strong Data In A Highly Differentiated Space

Chief Financial Officer recently sold US$91k worth of stock

Is Replimune Group (NASDAQ:REPL) Using Debt Sensibly?

Consensus revenue estimates decrease by 50%, EPS upgraded

Replimune Group, Inc. Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

Price target increased by 8.2% to US$14.67

Replimune Group, Inc., Annual General Meeting, Sep 04, 2024

Replimune Group, Inc. announced that it expects to receive $100.000032 million in funding

Chief Medical Officer notifies of intention to sell stock

Price target increased by 9.2% to US$14.56

Replimune Group, Inc. Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of Rp1 Plus Nivolumab in Anti-Pd1 Failed Melanoma

New minor risk - Share price stability

Replimune Presents Positive Data from Rp1 and Rp2 Clinical Programs At the 2024 American Society of Clinical Oncology (Asco) Annual Meeting

Replimune: Continuing To Justify The Bear Thesis (For Now)

Executive Chairman recently sold US$245k worth of stock

Replimune Group, Inc. Announces CEO Changes, Effective April 1, 2024

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Calculating The Intrinsic Value Of Replimune Group, Inc. (NASDAQ:REPL)

Now 25% undervalued after recent price drop

Price target decreased by 64% to US$17.22

New minor risk - Share price stability

Replimune Group, Inc. Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failure Melanoma and Non-Melanoma Skin Cancers

Chief Medical Officer recently sold US$80k worth of stock

Replimune Group, Inc. Announces the Appointment of Emily Hill as Chief Financial Officer

New major risk - Revenue and earnings growth

Replimune Group, Inc Announces Appointment of Emily Hill as Chief Financial Officer

Chief Business Officer exercised options and sold US$250k worth of stock

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $6.7 million.

Replimune Group, Inc., Annual General Meeting, Sep 06, 2023

Replimune Group, Inc. Announces Sander Slootweg Will Depart from Its Board of Directors

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Chief Business Officer notifies of intention to sell stock

Chief Strategy Officer notifies of intention to sell stock

Replimune Group, Inc. Appoints Veleka R. Peeples-Dyer to Its Board of Directors

Replimune Group, Inc. Presents RP1 Data from the IGNYTE Anti-PD1 Failure Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology Annual Meeting

Consensus revenue estimates fall by 42%

CEO & Director recently sold US$323k worth of stock

No longer forecast to breakeven

Insufficient new directors

Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?

A Look At The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Replimune Group, Inc. Announces Executive Appointments

Chief Business Officer exercised options and sold US$360k worth of stock

Price target increased to US$48.89

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

Replimune Group, Inc. announced that it has received $200 million in funding from Hercules Capital, Inc. and other investors

Replimune secures $200M term loan

Replimune: Recent Developments Strengthen Bull Thesis

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Replimune Group GAAP EPS of -$0.78 misses by $0.15

Replimune Group, Inc., Annual General Meeting, Sep 07, 2022

Replimune Group, Inc.(NasdaqGS:REPL) dropped from Russell 2000 Growth Index

Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate

Replimune Group, Inc. Announces the Resignation of Jason Rhodes from Its Board of Directors

Chief Commercial Officer recently sold US$156k worth of stock

We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate

Replimune Group, Inc. Announces Updated Data from Completed Cohorts of the Phase 2 Part of the IGNYTE Clinical Trial in Non-Melanoma Skin Cancer (Nmsc) and Melanoma

Replimune Group, Inc. Announces Departure of Dr. Otello Stampacchia from its Board of Directors

Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth

Chief Operating Officer notifies of intention to sell stock

Replimune: In The 'Buy Zone' Again